PDCD1 and head and neck squamous cell carcinoma: Currently, PD-1 drugs nivolumab and pembrolizumab, PD-L1 drugs atezolizumab, durvalumab, avelumab, and CTLA-4 ipilimumab and tremelimumab are tested in the treatment of HNSCC [108,109].